BioSpace News Archive

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl Spana, Ph.D., President and Chief Executive Officer, will participate in the H.C. Wainwright Global Life Sciences Virtual Conference

Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, will not proceed with further testing of the Aerpio Pharmaceuticals (Nasdaq: ARPO) drug, razuprotafib.

InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming 2021 H.C. Wainwright Global Life Sciences Conference

Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF)(“Predictmedix” or the “Company”) is pleased to provide a corporate update on its recent activities. The Company is proud to announce that it has closed a non-brokered private placement for gross proceeds of $1,090,085 in a strategic financing round to catalyze the Company’s operations as it scales its business.

Trxade Group, Inc. (NASDAQ:MEDS), a technology-enabled health services platform company focused on digitalizing the retail pharmacy experience, today announced that management will present at the following virtual investor conferences during the month of March 2021.

Sorrento Therapeutics, Inc., announced that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference:.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced results from preclinical studies of KER-050

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to seven new employees.

Seagen Inc. (Nasdaq:SGEN) today announced that it has been notified of an unsolicited “mini-tender” offer dated February 22, 2021, made by TRC Capital Investment Corporation, an Ontario, Canada corporation, to purchase up to 1,000,000 shares of Seagen’s common stock. According to TRC, its “mini-tender” offer price of $151.00 per share was approximately 4.28% below the closing price of Seagen’s common stock on February 19, 2021

Immune Regulation today announced it is rebranding as Revolo Biotherapeutics (“Revolo Bio”). The new brand, which will be implemented immediately, comes ahead of the advancement of the Company’s drug candidates into five clinical programs, including four Phase 2 trials.